17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
Given the emerging evidence on coronavirus SARS-CoV-2 variants and lessons learned from previous vaccine updates, international regulators have published a report highlighting the outcomes of their discussions on COVID-19 vaccines and the need for and strategy to update their composition. 31 May 2023
Demand for obesity drug therapies is surging. A new generation of medicines with efficacy rivaling bariatric surgery, with only minor tolerability issues, has replaced older drugs weighed down by significant cardiovascular side effects and mediocre efficacy. 30 May 2023
Privately-held Italian drugmaker Menarini has announced results from a new analysis of the pivotal EMERALD clinical study that suggest that oral single-agent Orserdu (elacestrant) may be effective in ER+, HER2- advanced or metastatic breast cancer patients with non-detected ESR1-mut whose disease has progressed within six months of treatment with a CDK4/6i. 30 May 2023
SKYcovion, the COVID-19 vaccine developed by SK bioscience, an entity of South Korean firm SK Chemicals, has been cleared for marketing by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). 30 May 2023
A £650 million ($802 million) war-chest to fire up the UK’s life sciences sector and drive forward the government’s priority to grow the economy has been unveiled by the Chancellor of the Exchequer Jeremy Hunt today. 26 May 2023
Hefei Tianhui Biotechnology (HTIT) has recently submitted a marketing authorization application (MAA) in China for the world’s first oral insulin for type 2 diabetes (T2D). 26 May 2023
Food and Drug Administration approved the oral antiviral Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. 26 May 2023
The UK’s Medicines and Healthcare products Regulator Agency (MHRA) today announced that new regulatory recognition routes for medicines will be established using approvals from Australia, Canada, the European Union, Japan, Switzerland, Singapore and the USA. 26 May 2023
US pharma giant Pfizer is to present data on more than 15 drugs—including six early pipeline assets—at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2 through June 6. 25 May 2023
Japanese drugmaker Daiichi Sankyo today announced that Vanflyta (quizartinib) has been approved in Japan for the treatment of acute myeloid leukemia (AML) that is FLT3-ITD mutation positive, with the news surprisingly pushing the firm’s shares down 4.4% to 4,582 yen 25 May 2023
PTC Therapeutics’ stock plummeted 19.6%, ending the regular session at $46.95, after it revealed top-line results from the MOVE-FA Phase III trial of vatiquinone in patients with Friedreich ataxia. 25 May 2023
Prime Minister Fumio Kishida has announced the government of Japan's pledge to contribute $200 million to the Global Health Innovative Technology Fund (GHIT Fund). 25 May 2023
The leading trade body for the British pharmaceutical industry has appointed a new president, current Pfizer UK managing director Susan Rienow. 25 May 2023
A new proposal from the US Department of Health and Human Services (HHS) is proposing steps to further drive down prescription drug costs in Medicaid, building on the Biden administration’s widespread efforts to lower medicine prices. 24 May 2023
As part of its growth strategy, UK biotech Fixed Phage, a developer of proprietary, anti-infective technologies, today announced the appointment Dr Neil Clelland as its new chief executive (CEO). 24 May 2023
Following a positive advisory committee vote last month, the US Food and Drug Administration (FDA) yesterday approved Xacduro (sulbactam for injection; durlobactam for injection), developed by Entasis Therapeutics, a subsidiary of Innoviva. 24 May 2023
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.